Deep Evidence-Based Analysis: Vitamin B12, D, and K Supplementation

PART 1 — VITAMIN B12

1A. The Four Forms: What They Actually Are

1B. B12's Two Core Mechanisms (Why Deficiency Is Dangerous)

1. Methionine regeneration / SAM production: Methylcobalamin is the cofactor for methionine synthase. Without it, homocysteine cannot be converted back to methionine, and S-adenosylmethionine (SAM) - the universal methyl donor - becomes depleted. The nervous system cannot use the backup betaine pathway for this conversion and is entirely dependent on the B12-dependent route. This leads to DNA and histone hypomethylation in neural tissue. - Basic Medical Biochemistry, p. 1394; Bradley & Daroff's Neurology
2. Myelin integrity via methylmalonyl-CoA mutase: Adenosylcobalamin is the cofactor for this mitochondrial enzyme. In deficiency, methylmalonyl-CoA accumulates and substitutes for malonyl-CoA in fatty acid synthesis, generating abnormal branched-chain fatty acids. These incorporate into phospholipids in the myelin sheath, causing structural destabilization - the biological basis of subacute combined degeneration of the spinal cord. - Basic Medical Biochemistry, p. 1394

1C. Cyanocobalamin: Is the "Toxic Cyanide" Claim True?

• Cyanocobalamin does contain a cyanide (CN⁻) ligand. When absorbed, the cyanide is released and excreted in urine as thiocyanate.
• The amount of cyanide released per therapeutic dose is physiologically trivial. A 1,000 µg cyanocobalamin tablet releases approximately 20 µg of cyanide - compare this to the 100-200 µg of cyanide released by one apple or in cigarette smoke.
• There is no documented clinical case of cyanide toxicity from therapeutic cyanocobalamin in people with normal renal function.
• The claim is sometimes extended to people with Leber's hereditary optic neuropathy (LHON) - and here there is a narrow legitimate concern: hydroxocobalamin is preferred in LHON because free cyanide may exacerbate the mitochondrial dysfunction. But this is a rare genetic condition, not a general population risk.
• For the average person - including vegetarians and those with GI disorders - cyanocobalamin is safe, well-studied, and approved globally as a pharmaceutical-grade B12.

1D. Which Form Has the Strongest Evidence?

• Cyanocobalamin has the longest evidence base, the most RCT data, and is the WHO standard for deficiency correction. It is stable at room temperature, cheap, and highly bioavailable.
• Hydroxocobalamin is preferred for injections (used in clinical deficiency correction in the UK and Europe), has a longer half-life in the body than cyanocobalamin injectables, and does not require decyanation. It is also the antidote for cyanide poisoning (irony noted).
• Methylcobalamin is extensively marketed as "the active, neurologically superior form." In practice, it is bioavailable orally and does not require decyanation, but head-to-head RCTs do NOT show superior clinical outcomes over cyanocobalamin in terms of deficiency correction, neurological recovery, or homocysteine reduction. One 2026 RCT (PMID 41548600) studying neuropathic outcomes in diabetic peripheral neuropathy with low B12 found oral methylcobalamin at both 1,000 and 2,000 µg effective, but did not compare to cyanocobalamin.
• Adenosylcobalamin is rarely used as a single supplement; it addresses the methylmalonyl pathway specifically but is less stable.

1E. Best Form for Specific Goals

1F. Oral vs. Sublingual vs. Injections

• No high-quality RCT has compared sublingual to oral B12 and found sublingual to be clinically superior.
• At the doses used in sublingual preparations (typically 1,000 µg), most of the tablet is swallowed and absorbed via the standard oral/passive diffusion route anyway.
• The sublingual route is not meaningfully different from oral for B12 in practice.
• This is largely a marketing distinction without proven clinical advantage over oral high-dose tablets. - No head-to-head RCTs with superiority endpoint found in PubMed

1G. Practical B12 Protocol for Confirmed Deficiency in a Lifelong Vegetarian

1. Initial repletion: If neurological symptoms are present or deficiency is severe, injections are preferable (hydroxocobalamin 1,000 µg IM, every other day for 2 weeks, then monthly - UK protocol). Alternatively, high-dose oral cyanocobalamin or methylcobalamin 1,000-2,000 µg/day for 3 months achieves repletion in those without ileal disease.
2. Maintenance: 1,000 µg/day orally, indefinitely (lifelong vegetarians have no dietary source).
3. Monitor: Serum B12, MMA, and homocysteine at 3 months, then annually. MMA is the most sensitive functional marker of tissue B12 sufficiency; serum B12 alone has 30-40% false positive/negative rates.
4. Folate: Ensure folate is adequate before or alongside B12 treatment. Folate supplementation without B12 in deficiency can precipitate or worsen neurological damage. - Bradley & Daroff's
5. TSH context: Thyroid function affects B12 metabolism; your mildly elevated TSH may contribute to fatigue even with normal T3/T4 - this is not a B12 interaction per se, but worth optimizing thyroid status separately.

PART 2 — VITAMIN D

2A. D2 (Ergocalciferol) vs. D3 (Cholecalciferol)

• Katzung's Pharmacology (16th ed.) states: "We prefer cholecalciferol (D3) to ergocalciferol (D2)."
• Multiple analyses show D3 produces higher and more sustained rises in 25(OH)D levels than equivalent doses of D2, likely because D3 has a longer half-life and binds vitamin D-binding protein more tightly.
• D2 has a faster clearance rate.
• Harrison's (22nd ed., 2025) and Bradley & Daroff's both note D3 "appears slightly more effective" though "both are suitable."
• The practical difference at the doses used for deficiency correction (1,000-4,000 IU/day) is modest but real. D3 is the clearly preferred form for supplementation.

2B. Daily vs. Weekly/Bolus Dosing

• Weekly vs. daily cholecalciferol were not significantly different in correcting hypovitaminosis D (OR = 1.5, 95% CI 0.3-6.9, p = 0.6).
• Both regimens restored levels; the difference was not clinically meaningful.
• High heterogeneity between studies (I² = 85.3%) limits firm conclusions.

"Treating older adults with daily small doses of vitamin D3, such as 400 IU, can prevent fractures and falls, as compared with large intermittent bolus doses of vitamin D3, which can result in increased incidence of fractures and falls."

• [Moderate evidence] - Acceptable for initial repletion over 8-12 weeks (total ~480,000-720,000 IU).
• Not ideal as indefinite maintenance; once replete, switch to 1,000-2,000 IU/day.
• The harm seen with bolus doses is mainly with very large single doses (>100,000 IU at once), not with 60,000 IU weekly.

2C. Can Vitamin D Worsen Bloating/IBS Symptoms?

• Vitamin D tablets and capsules, particularly those with certain excipients (PEG, sorbitol, mannitol, or lactose in some formulations), can cause loose stool or bloating in sensitive individuals.
• The vitamin D itself is unlikely to cause GI symptoms at standard doses.
• Some individuals with IBS report GI sensitivity to supplement excipients. Choose a simple oil-based softgel (e.g., olive oil or sunflower oil carrier, no sugar alcohols) to minimize this.
• There is theoretical interest in vitamin D's role in gut immune regulation and microbiome, but this is not clinically actionable yet.

2D. Risks of Excessive Vitamin D

"Vitamin D toxicity usually is observed only in patients taking doses in the range of 40,000 IU daily."

• At standard therapeutic doses (1,000-4,000 IU/day), toxicity is extremely rare.
• Monitoring: 24-hour urinary calcium is the most sensitive early marker. Levels >250 mg/24h warrant dose reduction.
• The safety margin for dietary D3 supplementation at 1,000-4,000 IU/day is large. The National Academy of Medicine sets the tolerable upper limit at 4,000 IU/day; the Endocrine Society considers up to 10,000 IU/day safe in supervised settings.
• For you: At 60,000 IU/week (≈8,571 IU/day equivalent), monitoring 25(OH)D every 6-8 weeks during initial repletion is prudent.

2E. How Long Does Correction Take?

• 25(OH)D levels typically rise within 4-8 weeks with adequate dosing.
• Normocalcemia (if impaired) normalizes within 1 week of instituting therapy.
• PTH and alkaline phosphatase may remain elevated for 3-6 months after correction. - Harrison's 22nd ed.
• Full correction of bone-related consequences may take longer.
• For your profile, monitor 25(OH)D at 8-10 weeks of supplementation to assess repletion.

PART 3 — VITAMIN K

3A. K2 with Vitamin D: Is It Necessary?

"Vitamin K does not consistently prevent progression of calcification, atherosclerosis or arterial stiffening. There may be some benefit in people with calcification at study entry. Studies were heterogeneous, with relatively short follow-up."

• The claim that "Vitamin D causes arterial calcium without K2" is overstated for healthy individuals.
• At standard vitamin D doses (1,000-4,000 IU/day), there is no clinical trial evidence that arterial calcification increases significantly in people with normal vitamin K status and normal diet.
• The mechanism is real at the protein level (MGP carboxylation), but translating this to clinical harm in healthy people supplementing D3 at normal doses is a significant extrapolation.
• Where K2 IS genuinely useful: Patients with chronic kidney disease, those on warfarin (though this complicates management), people with established vascular calcification, and patients on long-term high-dose D3 with very low dietary vitamin K.

3B. MK-4 vs. MK-7: Actual Evidence Differences

3C. Social Media Claims About "D Causing Artery Calcification Without K2"

1. The real biochemistry of MGP (genuinely vitamin K-dependent)
2. Animal models and in vitro evidence
3. Epidemiological associations in populations with very low K intakes
4. Clinical RCT evidence (which, as noted above, is inconsistent and unconvincing)

PART 4 — FAT ABSORPTION OF FAT-SOLUBLE VITAMINS

4A. How Much Dietary Fat Do You Actually Need?

• Studies show that taking vitamin D with a high-fat meal increases absorption by approximately 32-57% compared to a fat-free meal (this is well-replicated in pharmacokinetic studies).
• You do NOT need a high-fat meal. A moderate-fat meal (~10-15 g of fat) - such as a handful of nuts, a teaspoon of oil on food, or a small amount of dairy/egg - is sufficient to trigger adequate bile release and micellar formation.
• A few nuts (5-6 almonds, 2 walnuts) providing 5-8 g of fat is likely sufficient for clinically meaningful absorption improvement.
• For vitamin K2 (MK-7), the same principle applies.

4B. Advanced Delivery Formulations: Clinical Evidence

PART 5 — IBS/SIBO/GI CONTEXT

5A. Which Forms Are Better Tolerated?

• B12: Oral tablets and softchews are well-tolerated. Large tablets dissolving in the stomach are fine. Sublingual forms cause no more GI symptoms than swallowed tablets. Injections bypass GI entirely - relevant if SIBO significantly impairs absorption.
• Vitamin D3 softgels: Better tolerated than tablets for many IBS patients because they avoid excipients (fillers, binders, coating agents). Avoid formulations with sorbitol, xylitol, mannitol, or lactose if you react to these.
• K2 (MK-7): Generally well-tolerated. Soft gelatin capsules are preferred over hard-compressed tablets. Natto (fermented soy - a food source of MK-7) may cause bloating in SIBO-prone individuals due to fermentable carbohydrates, so supplement form is preferable.

5B. Which Supplements Most Likely Trigger GI Symptoms?

5C. Drug Interactions with Your Current Medications

• A non-absorbed antibiotic acting locally in the gut. It kills gut bacteria including those that synthesize menaquinones (vitamin K2).
• [Clinically relevant] Prolonged rifaximin courses may transiently reduce gut microbial K2 production. This is generally not clinically significant for coagulation (dietary K1 covers clotting factor carboxylation), but if you are relying on gut bacteria for K2, supplementation during and after rifaximin courses is a rational step.
• Rifaximin does not significantly affect B12 or vitamin D absorption.

• No known interactions with B12, D3, or K2 supplementation.

• No known interactions with these vitamins. May actually help absorption of oral supplements by improving gastric/intestinal mucosal integrity.

PART 6 — PRACTICAL EVIDENCE-BASED PROTOCOL FOR YOUR PROFILE

Form Recommendations

Dosing Philosophy

• If neurological symptoms are present or severe deficiency: Start with hydroxocobalamin injections (discuss with doctor), then switch to oral 1,000-2,000 µg/day maintenance.
• If mild deficiency / early: High-dose oral 1,000-2,000 µg/day cyanocobalamin or methylcobalamin is sufficient for repletion and maintenance.
• Lifelong daily maintenance required (no dietary source as a vegetarian).

• Initial repletion (your confirmed deficiency): 60,000 IU/week for 8-10 weeks (Indian standard protocol), OR 2,000-4,000 IU/day for 3-4 months.
• Maintenance after repletion: 1,000-2,000 IU/day indefinitely.
• Do NOT use very large single bolus doses (>100,000 IU at once) - evidence shows these can paradoxically increase fracture/fall risk.
• Reassess 25(OH)D after 8-10 weeks.

• 100-200 µg MK-7/day, taken with the main meal, particularly during and after rifaximin courses.
• Not mandatory if dietary leafy greens are adequate (K1 is sufficient for coagulation; K2 for bone/vascular is the uncertain part).

Meal Timing and Fat Intake

• Take D3 and K2 with your largest meal - no need for a specifically high-fat meal; regular Indian cooking with oil is sufficient.
• B12 can be taken at any time, with or without food.
• Do NOT take fat-soluble vitamins on an empty stomach if you have IBS; even if it does not impair absorption significantly, it can cause nausea.

Blood Tests to Monitor

Realistic Timelines for Improvement

WHAT SOCIAL MEDIA GETS WRONG: A SUMMARY

• Harrison's Principles of Internal Medicine, 22nd ed. (2025)
• Bradley and Daroff's Neurology in Clinical Practice
• Goodman & Gilman's Pharmacological Basis of Therapeutics, 16th ed.
• Basic Medical Biochemistry, A Clinical Approach, 6th ed.
• Katzung's Basic and Clinical Pharmacology, 16th ed.
• Yamada's Textbook of Gastroenterology, 7th ed.
• Sleisenger and Fordtran's Gastrointestinal and Liver Disease
• Harper's Illustrated Biochemistry, 32nd ed.
• Bortolussi-Courval et al. (2024) - Weekly vs. daily cholecalciferol meta-analysis [PMID 39396907]
• Vlasschaert et al. (2020) - Vitamin K and cardiovascular disease systematic review [PMID 32977548]
• Schijns et al. (2018) - Oral vs. IM B12 RCT [PMID 29931179]
• Sachdeva et al. (2025) - Parenteral vs. oral B12 systematic review [PMID 39964959]
• Mansour et al. (2026) - Oral methylcobalamin RCT in neuropathy [PMID 41548600]
• Nagpal et al. (2026) - B12 in vegetarian pregnant women MATCOBIND RCT [PMID 41850742]

Vitamin D Treatment: A Clinical Analysis for Your Exact Profile

Question 1: Is Oral Therapy Sufficient, or Is There a Meaningful Reason to Prefer Injections?

Question 2: Does IBS/SIBO Alone Justify Injections?

• Intact intestinal mucosal surface
• Adequate bile acid secretion (for micellar formation)
• Adequate dietary fat co-ingestion

Question 3: Detailed Comparison of the Three Approaches for Your Profile

Approach A: 60,000 IU Oral Weekly (×8 weeks)

Approach B: 2,000 IU Daily Oral

Approach C: Intramuscular Injection (600,000 IU, single or staggered)

Question 4: Is 60,000 IU Weekly for 8 Weeks Excessive for a 14.3 ng/mL Level?

• Harrison's 22nd ed.: "Severe vitamin D deficiency can be treated with pharmacologic repletion initially (50,000 IU weekly for 3-12 weeks)"
• Endocrine Society 2024 guidelines: 50,000 IU/week for 8 weeks for adults aged 19-70 with deficiency, then maintenance 1,500-2,000 IU/day
• StatPearls (NIH-hosted): "For serum level below 12 ng/mL - 6,000 IU daily or 25,000-50,000 IU weekly for 8 weeks"

Question 5: Your Mother Overshot After 3 Monthly Injections - Does That Mean You Will Too?

• [Mechanistic plausibility] There are known polymorphisms in CYP2R1 (hepatic 25-hydroxylase) and CYP24A1 (the inactivating enzyme) that affect both vitamin D conversion efficiency and clearance. A mutation in CYP24A1 reduces catabolism, causing 25(OH)D and 1,25(OH)2D to accumulate more than expected from a given dose. This is rare but does occur.
• [Mechanistic plausibility] If your mother has this variant, you have a 50% chance of inheriting it. This would manifest as higher-than-expected 25(OH)D rises, hypercalciuria, or symptoms from relatively modest doses.
• [Clinical practice reasoning] Without genetic testing, you cannot know for certain. However, the precautionary approach is rational: be conservative with initial dosing and monitor early.

Question 6: Is Daily Dosing Physiologically Superior to Large Intermittent Bolus Dosing?

1. Bolus dosing induces more catabolic metabolism: High single doses (e.g., 60,000 IU at once) cause a spike in calcitriol that triggers upregulation of CYP24A1 (the 24-hydroxylase enzyme that inactivates vitamin D metabolites) and FGF23 (which suppresses 1α-hydroxylase). This means a significant portion of the bolus is routed into inactive metabolite 24,25(OH)2-D. After a 600,000 IU bolus, 24,25(OH)2-D rose by ~50%; after the equivalent daily dose, it rose only ~30%.
2. 25(OH)D stability: Daily dosing produces a gradual, stable rise. Weekly dosing produces a weekly peak-trough cycle. Monthly dosing can produce significant inter-dose variation, especially for people with shorter 25(OH)D half-lives (~10 days vs. the average 20-25 days).
3. ESCEO 2025 guideline (published in Joint Bone Spine): "Daily administration is more physiological as regards to the endogenous synthesis of vitamin D and should be preferred as it allows to reach a steady state in a more stable way."
4. The falls/fractures paradox in older adults (Harrison's 22nd ed.): Large intermittent bolus dosing in the elderly increased falls and fracture incidence compared to small daily doses - likely because the acute calcitriol spike transiently impairs muscle function via VDR signaling dysregulation. This effect has not been replicated in young adults, so the falls risk is not directly applicable to you - but it illustrates that the biology of large spikes is not simply "more is better."
5. For respiratory infections (meta-analysis PMID 30675873): Daily vitamin D supplementation reduced respiratory infection risk; bolus dosing was not effective for this endpoint - a signal that biological activity differs between dosing patterns.

• For initial deficiency correction (your current situation), the 60,000 IU/week × 8-week protocol is evidence-based and appropriate. The catabolic effect of large doses matters less when you are genuinely deficient and need to raise levels quickly.
• For long-term maintenance, daily dosing (1,500-2,000 IU/day) is physiologically superior and now explicitly preferred in multiple 2024-2025 guidelines. Once you are replete, switch to daily.
• Avoid monthly or quarterly bolus dosing for maintenance - this is the regimen most associated with fluctuation, catabolic induction, and unexpected clinical outcomes.

Question 7: What Would I Choose in Your Exact Situation?

• Total 8-week dose: ~224,000 IU (vs. 480,000 IU with weekly protocol)
• Slower but steady rise - expected to reach 25-35 ng/mL by 8 weeks, which is exactly the target
• More physiologically stable (daily > weekly pharmacokinetics)
• No peak-trough fluctuation
• Zero overshoot risk from a single forgotten dose or early cessation
• Respects your family history of sensitivity by using a lower total dose
• 4,000 IU/day is below the National Academy of Medicine's "tolerable upper limit" for daily intake and well within normal supplementation range
• StatPearls notes 6,000 IU/day as an acceptable correction dose for < 12 ng/mL; at 14.3 ng/mL, 4,000 IU/day is entirely appropriate

Monitoring Protocol

Key Takeaway Summary

• Harrison's Principles of Internal Medicine, 22nd ed. (2025): treatment dosing protocol, bolus dose harms
• Endocrine Society 2024 Clinical Practice Guidelines: dosing by age and severity
• StatPearls, Vitamin D Deficiency (NIH Bookshelf): < 12 ng/mL and < 20 ng/mL treatment protocols
• ESCEO 2025 (Joint Bone Spine): daily preferred over intermittent for physiological stability
• German Federal Institute for Risk Assessment (BfR) 2024-2025: pharmacokinetics of bolus vs. daily, CYP24A1/FGF23 induction
• PMC5240054: Oral vs. IM vitamin D in apparently healthy adults - 25(OH)D comparison at 6 and 12 weeks
• Frontiers in Nutrition (2025): safety and efficacy of cholecalciferol regimens, summary of clinical evidence
• Frontiers in Endocrinology (2018): Vitamin D toxicity - case series, dose thresholds, inter-individual variability